comprehensive -WSS

comprehensive

author：fashion 2025-09-06 04:38:18 - browse：51596

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： CDC's new outbreak response network to include Northeastern

WSS

It's been 20 years since Dolly the sheep. Where's my clone?

Elizabeth Holmes banned from government health programs

Thermo Fisher plant for manufacturing gene therapies to expand

Dewpoint Therapeutics lays off staff after losing partnerships

Emergency workers more likely to restrain Black patients: study

FDA panel to weigh approval of NurOwn, controversial ALS drug

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Prior authorization will have to move faster under new Biden rule

Drug repurposing or repositioning? The language matters

CommonSpirit Health keeps growing, even as it loses money

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech lab space demand falls sharply

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Merck, J&J, and long Covid

The high cost of giving birth even with insurance

Francis Collins on trust in science and how Covid communications failed

leisure time

What Congress can do to address the rural doctor shortage

Francis Collins on trust in science and how Covid communications failed

Intarcia’s device

The surgeon had a dilemma only a Nazi medical text could resolve

STAT Virtual Event: Putting AI to the Test

Elizabeth Holmes banned from government health programs

explore

hotspot

hotspot

focus